Floatz logo

Osimertinib

Hepatocellular Carcinoma

AstraZenecaSmall moleculePhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
81/ 100

Competitive context

498 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Xaliplatin
Li Qiang
Phase 4BBB
Fluorouracilum
Li Qiang
Phase 4BBB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

Osimertinib is also rated in:

non-small cell lung carcinomaActive
BB
Indicative · Phase 4
71 / 100
View asset →
lung adenocarcinomaDormant
BB
Indicative · Phase 2
69 / 100
View asset →
adenocarcinomaActive
BB
Indicative · Phase 2
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →